242 related articles for article (PubMed ID: 34091051)
1. Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8
Liu B; Zhu X; Kong L; Wang M; Spanoudis C; Chaturvedi P; George V; Jiao JA; You L; Egan JO; Echeverri C; Gallo VL; Xing J; Ravelo K; Prendes C; Antolinez J; Denissova J; Muniz GJ; Jeng EK; Rhode PR; Wong HC
Mol Ther; 2021 Oct; 29(10):2949-2962. PubMed ID: 34091051
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells.
Chaturvedi P; George V; Shrestha N; Wang M; Dee MJ; Zhu X; Liu B; Egan J; D'Eramo F; Spanoudis C; Gallo V; Echeverri C; You L; Kong L; Fang B; Jeng EK; Rhode PR; Wong HC
Mol Ther; 2022 Mar; 30(3):1171-1187. PubMed ID: 35051615
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
[TBL] [Abstract][Full Text] [Related]
4. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model.
Berger A; Colpitts SJ; Seabrook MSS; Furlonger CL; Bendix MB; Moreau JM; McKillop WM; Medin JA; Paige CJ
J Immunother Cancer; 2019 Dec; 7(1):355. PubMed ID: 31856922
[TBL] [Abstract][Full Text] [Related]
6. The deubiquitinase Otub1 controls the activation of CD8
Zhou X; Yu J; Cheng X; Zhao B; Manyam GC; Zhang L; Schluns K; Li P; Wang J; Sun SC
Nat Immunol; 2019 Jul; 20(7):879-889. PubMed ID: 31182807
[TBL] [Abstract][Full Text] [Related]
7. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
[TBL] [Abstract][Full Text] [Related]
8. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
[TBL] [Abstract][Full Text] [Related]
10. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Otegbeye F; Ojo E; Moreton S; Mackowski N; Lee DA; de Lima M; Wald DN
PLoS One; 2018; 13(1):e0191358. PubMed ID: 29342200
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice.
Lucas PJ; Kim SJ; Mackall CL; Telford WG; Chu YW; Hakim FT; Gress RE
Blood; 2006 Oct; 108(8):2789-95. PubMed ID: 16788095
[TBL] [Abstract][Full Text] [Related]
13. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
14. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
Liu B; Kong L; Han K; Hong H; Marcus WD; Chen X; Jeng EK; Alter S; Zhu X; Rubinstein MP; Shi S; Rhode PR; Cai W; Wong HC
J Biol Chem; 2016 Nov; 291(46):23869-23881. PubMed ID: 27650494
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.
Yajima T; Nishimura H; Wajjwalku W; Harada M; Kuwano H; Yoshikai Y
Int J Cancer; 2002 Jun; 99(4):573-8. PubMed ID: 11992548
[TBL] [Abstract][Full Text] [Related]
16. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
17. Targeting activity of a TCR/IL-2 fusion protein against established tumors.
Wen J; Zhu X; Liu B; You L; Kong L; Lee HI; Han KP; Wong JL; Rhode PR; Wong HC
Cancer Immunol Immunother; 2008 Dec; 57(12):1781-94. PubMed ID: 18369620
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
[TBL] [Abstract][Full Text] [Related]
19. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo.
Huntington ND; Legrand N; Alves NL; Jaron B; Weijer K; Plet A; Corcuff E; Mortier E; Jacques Y; Spits H; Di Santo JP
J Exp Med; 2009 Jan; 206(1):25-34. PubMed ID: 19103877
[TBL] [Abstract][Full Text] [Related]
20. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.
Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W
J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
